Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 6/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27240046 | 0.93 | MEN1 (0.40) | MEN1LMNAKMT2ASMN1; SMN2CSF1R | |
| SCHEMBL27240069 | 0.92 | CSF1R (0.40) | CSF1RGRM5PPARG | |
| SCHEMBL23287985 | 0.92 | BTK (0.40) | PPARGPPARANR1H4CYP2C9EGLN1 | |
| SCHEMBL27240101 | 0.91 | CSF1R (0.47) | MEN1KMT2ACSF1RNPC1PPARG | |
| SCHEMBL23287969 | 0.91 | GRM5 (0.45) | SMN1; SMN2CSF1RGRM5NPC1MAPT | |
| SCHEMBL23273761 | 0.91 | CSF1R (0.42) | CSF1RGRM5 | |
| SCHEMBL27240078 | 0.91 | GRM5 (0.51) | CSF1RGRM5 | |
| SCHEMBL29827331 | 0.90 | GRM5 (0.42) | MEN1LMNAKMT2ASMN1; SMN2CSF1R | |
| SCHEMBL23273849 | 0.90 | GRM5 (0.42) | MEN1LMNAKMT2ASMN1; SMN2CSF1R | |
| SCHEMBL27240172 | 0.90 | GRM5 (0.39) | SMN1; SMN2CSF1RGRM5NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190824-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-06-13 | — | — | US | disclosed |
| WO-2021080013-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190824-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | KCNJ11, KCNJ1, KCNJ2 | MEN1 2570/4885LMNA 1044/4885KMT2A 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.